|
Antibody | Mechanism of action | Representative Phase II studies | Phase III studies |
Population | Treatment | Results | Population | Treatment | Results |
|
Bevacizumab (Genentech/Roche) | Binds to VEGF Antiangiogenic Immunosuppressive | Refractory () [145] | Monotherapy () With chemotherapy () | RR 16% PFS 5.5 m OS 6.9 m | First-line ICON 7 [146] | Carboplatin/Paclitaxel versus Carboplatin/Paclitaxel/Bevacizum ab | Median PFS 17.3 m versus 19 m, 10.3 m versus 11.2 m versus 14.1, |
| | Refractory () [147] | Monotherapy | RR 16% PFS 4.4 m OS 10.7 | GOG 218 [148] | Carboplatin/Paclitaxel versus Carboplatin/Paclitaxel/Bevacizum ab versus Carboplatin/Paclitaxel/Bevacizum ab + Bevacizumab maintenance |
|
Oregovomab (AltaRex Corp) | Binds to CA125 Development of a humoral and cellular antitumor response | 2nd line treatment () [149] | With chemotherapy | Development of T cell response was associated with improved survival | Maintenance after first-line () [150] | Oregovomab versus placebo | Median PFS 13.3 m versus 10.3 m, |
|
| | | | | Maintenance after first-line Residual<2 cm, CA125 < 65 after 3rd cycle, CA1 at entry () | Oregovomab versus placebo | Awaited |
|
Trastuzumab (Genentech) | Binds to HER2 extracellular domain | Recurrent () [141] | Monotherapy | RR 7.3% PFS 2 m | | | |
|
Pertuzumab (Genentech) | Inhibitor of HER dimerization | 87% platinum-resistant () [151] | monotherapy | RR 4.3% PFS 6.6 w | | | |
|
Cetuximab (Bristol-Myers Squibb) | EGFR inhibitor | First-line () [152] | Combination with paclitaxel/carboplatin | PFS 14.4 m | | | |
|
Matuzumab (Merck/Serono/Takeda) | EGFR inhibitor | Platinum-resistant () [153] | Monotherapy | RR 16.2 m TTP 54d OS 13.3 m | | | |
|